 HOUSTON, Jan. 21, 2021 GLOBE NEWSWIRE -- Salarius Pharmaceuticals, Inc. Nasdaq: SLRX, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaqs Listing Rule 5550a2 pertaining to the minimum bid price requirement for continued listing on the Nasdaq Capital Market. 